The Oncology Institute, Inc.
TOI
$4.59
$0.122.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 35.37% | 27.79% | 21.67% | 17.53% | 17.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 35.37% | 27.79% | 21.67% | 17.53% | 17.64% |
| Cost of Revenue | 34.72% | 25.60% | 20.77% | 17.96% | 20.54% |
| Gross Profit | 39.18% | 41.55% | 27.10% | 15.18% | 3.19% |
| SG&A Expenses | 3.49% | -2.09% | -7.90% | -7.90% | -7.70% |
| Depreciation & Amortization | 2.95% | 10.45% | 14.00% | 9.34% | 8.03% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.07% | 18.80% | 13.47% | 10.97% | 12.44% |
| Operating Income | 37.21% | 39.98% | 35.36% | 26.27% | 16.22% |
| Income Before Tax | 32.19% | 6.07% | 5.87% | 7.95% | 11.88% |
| Income Tax Expenses | -- | -- | 58.28% | 26.82% | -- |
| Earnings from Continuing Operations | 32.39% | 6.27% | 5.63% | 7.90% | 11.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 32.39% | 6.27% | 5.63% | 7.90% | 11.79% |
| EBIT | 37.21% | 39.98% | 35.36% | 26.27% | 16.22% |
| EBITDA | 43.03% | 45.87% | 40.65% | 30.18% | 18.86% |
| EPS Basic | 46.10% | 20.34% | 16.71% | 14.45% | 13.82% |
| Normalized Basic EPS | 43.84% | 26.49% | 22.63% | 19.84% | 18.84% |
| EPS Diluted | 46.74% | 21.05% | 17.11% | 13.73% | 13.41% |
| Normalized Diluted EPS | 43.84% | 26.49% | 22.63% | 19.84% | 18.84% |
| Average Basic Shares Outstanding | 30.00% | 23.01% | 15.25% | 8.64% | 2.62% |
| Average Diluted Shares Outstanding | 30.00% | 23.01% | 15.25% | 8.64% | 2.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |